骨髓细胞DNA倍体及增殖周期的检测在骨髓增生异常综合征诊断中的作用

Analysis of bone marrow DNA ploidy and proliferation period in myelodysplastic syndromes

[目的 ]探讨DNA倍体及增殖周期在骨髓异常增生综合征 (MDS)的变化及意义。 [方法 ]应用流式细胞仪 (FCM )测定MDS组和良性血液病组骨髓细胞的DNA倍体及增殖周期。 [结果 ]良性血液病组无一例检出DNA非整倍体 ,MDS组DNA非整倍体检出率 (2 5 .7% )明显高于对照组。MDS组骨髓细胞G0 /G1期百分比明显高于对照组 (P <0 .0 5 ) ,S +G2 /M期百分比明显低于对照组(P <0 .0 5 )。 [结论 ]流式细胞仪DNA倍体及周期分析是MDS一个重要的诊断指标 ,对于MDS的疗效。

To study the variation and significance of DNA anueploidy and proliferation period in myelodysplastic syndromes(MDS). The bone marrow cell of MDS group and non-malignant hematologic disease (served as control) were evaluated by flow cytometry. The incidence of FCM-DNA aneuploidy was 25.7% in MDS patients and zero in the control group. The percentage of the bone marrow cells in MDS is remarkable higher than that of the control groups at G 0/G 1 stage ( P <0.05), but markedly lower than that of the control group at (S+G 2/M) stage ( P <0.05). [Conclusion] FCM-DNA Aneuploidy is a new diagnostic and prognostic factor in MDS.